Clinical Research Directory

Inclusion Criteria: 1. Age greater than or equal to 18 years at inclusion 2. Cytological or histological confirmation of the diagnosis of invasive squamous cell carcinoma of the head and neck 3. One of the following locations: oral cavity, oropharynx (known p16 status), larynx or hypopharynx 4. Cancers of unknown primary (CUP) of the head and neck are accepted 5. Metastatic (stage IVc) or recurrent disease in patients ineligible for curative surgical treatment or radiotherapy 6. Indication of a 2nd line after pembrolizumab +/- chemotherapy 7. Chemotherapy-free interval ≥ 3 months 8. ECOG Performance Index (Performance Index) of 0, 1 or 2 9. Patient with a life expectancy of at least 12 weeks 10. Documented progression of a measurable tumor target according to RECIST 1.1 11. Correct biology 12. Patient (male or female of childbearing potential) using a highly effective contraceptive method 13. Willingness and ability to comply with the visit schedule, treatment regimens, examinations and other procedures planned in the study 14. Patient enrolled in a health insurance plan or beneficiary of such a plan 15. Signed informed consent obtained before inclusion (after giving clear, fair and appropriate information) Exclusion Criteria: 1. Other histology 2. Nasal, paranasal and nasopharyngeal cavities 3. Symptomatic or active brain parenchymal metastases or leptomeningeal tumors 4. Grade ≥2 neuropathy 5. Patients may have previously received radiotherapy. A minimum period of 2 weeks is necessary between palliative or analgesic radiotherapy and the start of treatment 6. Clinically significant heart disease or congestive heart failure NYHA (New York Heart Association) class 2 or greater. Patients must not have had unstable angina (symptoms of angina at rest) or new angina in the last 3 months or myocardial infarction in the last 6 months. 7. History of other primary malignancies, except curatively treated malignancies with no evidence of recurrence, within 3 years before the first dose of treatment and a low potential risk of recurrence or non-recurrent skin cancer. melanoma or lentigo maligna properly treated without evidence of disease or carcinoma in situ adequately treated without evidence of disease. A history of T1 grade bladder cancer or T1 grade kidney cancer is accepted. Cervical carcinoma in situ or breast cancer in situ are accepted. Patients with papillary thyroid carcinoma, basal cell skin carcinoma are accepted. A history of prostate cancer is allowed if it is less than or equal to stage T2N0M0 and a Gleason score of 6. 8. Known hypersensitivity to the active substance or excipient of the treatments under study 9. Any uncontrolled intercurrent pathology 10. Any psychiatric illness/social situation that may limit compliance with study procedures or prevent the patient from giving written informed consent 11. Any chemotherapy or radiotherapy performed within 4 weeks of the first dose of study drug, except palliative radiotherapy to a non-target lesion 12. Major surgery within 4 weeks before the first administration of treatment. Local palliative surgery for isolated lesions is tolerated 13. Phenytoin prescribed for prophylaxis 14. Administration of a live attenuated vaccine within 30 days before the first administration of study treatment, as well as during the duration of study treatment and up to 6 months after the last dose of treatment 15. Participation in another clinical trial of an investigational treatment during the 4 weeks preceding the first administration of the study treatment 16. Pregnant or breastfeeding women 17. Women of childbearing potential must have a negative pregnancy test within 72 hours before starting treatment. 18. Patients presenting hemorrhagic tumor 19. History of allergy to red meat or tick bites or positive results of tests for IgE antibodies against cetuximab (α-1-3-galactose) 20. Patient presenting interstitial lung disease 21. History of organ transplant 22. Concomitant treatment with Hypericum